California Stem Cell Agency Suspends Harvard Scientist from its Award Process following Allegations of Research Misconduct
The scientist served on the panel that makes the de facto decisions on requests for tens of millions of dollars
Twenty-seven thousand people viewed a 2022 Tedx talk by Khalid Shah.
Following allegations of research misconduct, California’s $12 billion stem cell and gene therapy agency removed a Harvard professor this afternoon from the group of scientists who make decisions on applications for tens of millions of dollars from state researchers.
The allegations involve Khalid Shah, director of the Center for Stem Cell and Translational Immunotherapy at Brigham and Women's Hospital in Massachusetts. He is one of 226 scientists who make the de facto decisions about funding awards from the California Institute for Regenerative Medicine (CIRM).
Shah is “facing accusations that more than two dozen papers he co-authored contain scientific images that appear doctored or copied,” the Wall Street Journal reported today.
“Elisabeth Bik, a microbiologist and science image expert, this week sent accusations about 28 studies Shah co-authored to research integrity officials at both institutions and the journals that published them,” the article continued.
Bik’s studies of Shah’s work first appeared on PubPeer, a San Francisco, CA., public benefit corporation whose goal is “to improve the quality of scientific research.”
Keep reading with a 7-day free trial
Subscribe to The California Stem Cell Report to keep reading this post and get 7 days of free access to the full post archives.